Market Research Reports, Inc. Pharmaceutical Industry in China Q2 2013 - Cutting-Edge Analysis, New Report Launched

Market Research Reports, Inc. has announced the addition of “Pharmaceutical Industry in China Q2 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” research report to their offering.


Lewes, DE -- (SBWIRE) -- 11/26/2013 -- Pharmaceutical Industry China Q3 2013 – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges report provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 196 tables & figures within 145 pages. The Chinese biopharmaceutical market is presented as follows:

By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:
Company financials, sales & revenue figures – historical to Q2-2013
China GDP, economic growth, export (bulk drug, formulations) figures
Indian health expenditure as a function of GDP
Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:
Key strengths, weaknesses and threats influencing leading player position within the market
Top Five Contract Pharmaceutical Export Markets of China
Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
Multinational penetration into the Chinese Pharma Market
Comprehensive product portfolios, R&D activity and pipeline therapeutics
M&A activity and future strategies of top Chinese pharmacos
Economic indicators, trade policy, merchandise and commercial trade statistics
Gross Domestic Product of China, historic and projection analysis
Chinese economic outlook in comparison to advanced economies
Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
Prescription drug sales distribution channels in China
Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.
Amoytop Biotech
Active Pharmaceutical Products
Beijing Continent Pharmaceuticals
FusoGen Pharmaceuticals
Shanghai Huaguan Biochip
SiBiono GeneTech
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson Medical

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:
- An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
- Knowledge of how the Chinese pharma market will integrate into the global healthcare market
- Information on key regulatory and government policies
- Data on levels of private and publically funded biopharma studies in China
- Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

Spanning over 145 pages, table and figures; “Pharmaceutical Industry in China Q2 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” report cover the Chronic Disease Prevalence Statistics, Business Environment, Chinese Pharmaceutical Market, Government and Regulation Environment, China – Third Largest Pharma Market 2012, Global Pharmaceutical Companies Interest in China, Chinese Pharmaceutical Companies, Drivers, Restraints, Challenges and Opportunity Analysis. The report include 16 Companies; Amoytop Biotech, Active Pharmaceutical Products, Beijing Continent Pharmaceuticals, FusoGen Pharmaceuticals, Shanghai Huaguan Biochip, SiBiono GeneTech, Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Johnson & Johnson Medical, Merck, Novartis, Pfizer, Roche.

For more information visit:

Find all Pharmaceuticals and healthcare reports under a single page.

Find all Country Overview (Pharma & Healthcare) reports under a single page at:

About Market Research Reports, Inc.
Market Research Reports Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.